Changing Treatment Paradigms in Smoldering and NDMM
Release Date: November 08, 2019
Expiration Date: November 08, 2020
Expected time to complete this activity as designed: 15 minutes
There are no fees for participating in or receiving credit for this online activity.
There have been many changes in the treatment of smoldering and newly diagnosed multiple myeloma (NDMM). In this activity, Dr. Jonathan Kaufman explains the most important developments and how they will impact your practice. He also covers the changes in frontline treatment and the most important developments of newly diagnosed patients. Lastly, Dr. Kaufman discusses therapy options for ineligible and eligible transplant patients.
This activity is designed for multidisciplinary healthcare providers in the community setting, including hematologists, pharmacists and other allied healthcare professionals who provide care to patients with smoldering and newly diagnosed multiple myeloma.
Upon completion of this educational activity, participants should be able to:
- Outline current and emerging approaches to the management of smoldering to NDMM, focusing on those frontline regimens identified in National Comprehensive Cancer Network (NCCN) guidelines
- Evaluate safety and efficacy of emerging multi-drug combinations in NDMM patients
- Identify patient- and disease-specific factors that must be considered when selecting therapeutic regimens for NDMM patients, including planning for the transition to maintenance therapy
Changing Treatment Paradigms in Smoldering and NDMM – Jonathan L. Kaufman, MD
Instructions for Participation and Credit
This activity is eligible for credit through November 08, 2020. After this date, this activity will expire and no further credit will be awarded.
- Read the target audience, learning objectives, and faculty disclosures.
- You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
- Complete the educational content as designed.
- Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
- Complete the activity evaluation survey to provide feedback and information useful for future programming.
- Certificates for CME may be printed immediately after successfully completing the post-test and activity evaluation. Pharmacist credit will be uploaded to CPE Monitor 4 weeks following receipt of a completed, qualified form.
Jonathan L. Kaufman, MD
Associate Vice-Chair for Quality and Safety
Department of Hematology and Medical Oncology
Emory University School of Medicine
Dr. Jonathan Kaufman received his medical degree from the Medical College of Georgia in Augusta. He completed his residency in internal medicine and his fellowship in hematology and oncology at Emory University in Atlanta, Georgia. Dr. Kaufman is Associate Professor and Associate Vice-Chair for Quality and Safety of the Department of Hematology and Medical Oncology at Emory University School of Medicine.
Dr. Kaufman is board certified in hematology and medical oncology. He is a member of the Discovery and Developmental Therapeutics Research Program at Winship Cancer Institute. He also holds memberships with the American Society of Clinical Oncology and American Society of Hematology. Dr. Kaufman's practice includes treating multiple myeloma and amyloidosis patients at Emory University Hospital. As a network physician, he started practicing with Emory Healthcare in 2005. He is also an active clinical and translational researcher in the fields of multiple myeloma, amyloidosis, and bone marrow transplant.
Accreditation Statement: MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation Statement: MediCom Worldwide, Inc. designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 0.25 contact hours of Continuing Education Credit. Universal Activity Number: 827-0000-19-022-H01-P. Knowledge-based CPE activity.
In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when claiming credit for a CPE program.
As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.
Dr. Jonathan Kaufman has received honoraria related to formal advisory activities from Incyte Corporation and T6 Therapeutics, as well as consultant fees from Amgen Inc., Celgene Corporation, Janssen Pharmaceuticals, Inc., Sanofi, and Takeda Oncology. He has received grant support related to research activities from Amgen, Celgene, and Janssen.
Planning Committee Disclosures
The individuals listed below from MediCom Worldwide, Inc. reported the following for this activity: Andrea Mathis, Project Manager, Joan Meyer, RN, MHA, Executive Director, and Andrew D. Bowser, ELS, CHCP, Medical Writer, have no relevant financial relationships.
Peer Reviewer Disclosure
In accordance with MediCom Worldwide, Inc. policy, all content is reviewed by external independent peer reviewers for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.
If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at email@example.com
Provided by MediCom Worldwide, Inc.
This activity is supported by an educational grant from Celgene Corporation.
©2019 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242.
No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.